OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial ...
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of ...
Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q ...
Hello! This is the Entre Note editorial department.In addition to operating the independent business and startup support site ...
<?xml encoding="utf-8" ?> Pacific Biosciences PACB reported third-quarter financial results on Wednesday. The transcript from ...
Delcath Systems Q3 earnings preview: topline beat odds look strong as CHOPIN trial success boosts growth outlook. Read here ...
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® ...
There used to be an honorable way to try to profit from online infamy: selling nearly worthless memecoins. The machines could take it over.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported third quarter 2026 financial results and preliminary data from its multiple-ascending dose (MAD) clinical study for its potential best ...
Hello, this is SOLOMICS."Can a company with one employee and a $1 billion valuation (a unicorn) be created?"In the age of AI, ...
<?xml encoding="utf-8" ?> AppLovin APP reported third-quarter financial results on Wednesday. The transcript from the company ...
Palisade Bio's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. I rate PALI stock as Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results